Shots:
- Chengdu Origen & Vanotech has reported the first pts dosing in Vanotech-led P-I (VAN-2401) trial assessing KH658 for wet age-related macular degeneration (wet AMD) in the US
- The P-I trial will assess safety, tolerability, & efficacy of single suprachoroidal KH658 gene therapy in ~9 previously treated wet AMD pts that are responsive to anti-VEGF therapy
- KH658 is a recombinant AAV vector encoding a human VEGF receptor fusion protein, which showed prolonged retinal transgene retention & prevention of disease progression in preclinical wet AMD models after suprachoroidal administration
Ref: Globenewswire| Image: Vanotech
Related News:- Recursion Presents Preliminary P-Ib/II (TUPELO) Trial Data of REC-4881 for Familial Adenomatous Polyposis (FAP) at DDW 2025
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for the Full Press Release
